Chapter 07 · Operations & Adoption

Operations & Adoption as a reviewable surface.

Operations and adoption in Medicines focus on whether teams can use the system consistently, challenge it safely, and learn from real use.

Read the workspace →AI in Healthcare hub
Focus: medicine lifecycle · PV · benefit-riskRisk: signal distortion and weak traceabilityBridge: case · evidence · action
Medicines traceCaseSignalBenefitRiskActionReviewAIsystemsource to workflow to evidence to review
AI in Healthcare/Medicines, Pharmacovigilance & Lifecycle AI/Operations & Adoption
MedicinesWorkspaceOverviewUse CasesDataModelValidationGovernanceOperationsMarketUpdates
/ 07

Operations & Adoption chapter.

Medicines

Operations and adoption in Medicines focus on whether teams can use the system consistently, challenge it safely, and learn from real use.

/ A

What this page maps.

operating content
Role fit

Role fit

Names who uses the system, what changes in daily work, and which records are created.

Training and literacy

Training and literacy

Explains safe use, limitations, review expectations, reporting routes, and prohibited uses.

Learning loop

Learning loop

Turns monitoring, incidents, user feedback, and weekly signals into revisions of policy, workflow, and evidence requirements.

/ B

Governance questions.

review logic
Question

What decision or record does this operations & adoption surface influence, and who owns that decision?

Question

Which evidence is needed before routine use in Medicines, and where is it retained?

Question

What signal triggers review, restriction, escalation, or retirement?

/ evidence

Evidence-ready minimum record.

iFeed use
Minimum record
OwnerNamed operational, clinical, technical, and governance owners.
UseClear intended use, user group, workflow point, and excluded use.
RiskRisk tier, rationale, residual risks, controls, and escalation route.
EvidenceSource claims, validation basis, limitations, approval decision, and review date.
/ sources

Source anchors and claim boundary.

official first

These anchors support the source layer for this page. iFeed interpretation remains separate from source facts and does not replace legal, regulatory, clinical, or product-specific advice.

Source anchors
FDA Artificial Intelligence for Drug Development →EMA reflection paper on AI in medicines lifecycle →ICH E2B(R3) Individual Case Safety Report →ICH E6(R3) Good Clinical Practice →NIST AI Risk Management Framework →
← Governance & RiskMarket & Actors →